Vitreosolve: A Comprehensive Analysis of its Development and Discontinuation in Pharmacologic Vitreolysis

I. Introduction to Vitreosolve

A. Overview and Identification

Vitreosolve was an investigational pharmaceutical agent developed within the field of pharmacologic vitreolysis. This field seeks to utilize non-surgical methods, primarily intravitreal drug delivery, to modify the structure of the vitreous humor and its interface with the retina, thereby treating or preventing various ocular pathologies associated with vitreoretinal adhesion or traction.[1] The vitreous humor, a gel primarily composed of water, collagen fibrils, and hyaluronan, plays a crucial role in maintaining eye structure but can contribute to diseases like diabetic retinopathy, macular holes, and vitreomacular traction when age-related or pathological changes occur, particularly incomplete posterior vitreous detachment (PVD).[1]

Vitreosolve was distinctively classified as a non-enzymatic agent, setting it apart from other vitreolytic approaches explored concurrently, such as those employing enzymes like plasmin, microplasmin (ocriplasmin), hyaluronidase, or dispase to cleave specific molecular components of the vitreous or vitreoretinal interface.[1] It was identified as a proprietary small molecule formulation belonging to the carbomide family, specifically characterized as being urea-based.[1] The intended route of administration was via intravitreal injection directly into the vitreous cavity.[10]

The development of Vitreosolve occurred during a period of significant interest in finding alternatives to surgical vitrectomy for managing vitreoretinal interface disorders. Surgical approaches, while effective, carry risks and are not always suitable.[7] Pharmacologic vitreolysis offered the potential for a less invasive treatment paradigm.[1] Vitreosolve's non-enzymatic, urea-based approach represented a different strategy compared to enzymatic agents like ocriplasmin, potentially offering a distinct efficacy and safety profile.[1]

B. Developer

The development of Vitreosolve was undertaken by Vitreoretinal Technologies, Inc. (VRT), identified as a specialty pharmaceutical company headquartered in Irvine, California.[1] VRT's pipeline reportedly focused on ophthalmic conditions including diabetic retinopathy, glaucoma, and retinitis pigmentosa.[15] In November 2007, the company announced the closure of an $8.8 million Series A financing round involving De Novo Ventures and private investors, funds intended to support the advancement of its pipeline candidates, including Vitreosolve, into Phase 3 trials.[15]

C. Intended Indications

The primary therapeutic goal for Vitreosolve, particularly in its late-stage clinical trials, was the induction of posterior vitreous detachment (PVD) in patients diagnosed with non-proliferative diabetic retinopathy (NPDR) who did not have a pre-existing PVD.[1] This was positioned as a preventative strategy against the progression to proliferative diabetic retinopathy (PDR), a more severe, vision-threatening stage of the disease.[10]

The rationale underpinning this preventative approach was based on clinical observations suggesting that the presence of a complete PVD is protective against the development or worsening of PDR.[4] Studies indicated that patients with spontaneous PVD had lower rates of progression to PDR, potentially because the separation removes the scaffold necessary for neovascular growth and alters the proximity of growth factors like vascular endothelial growth factor (VEGF) to the retina.[10] Vitreosolve aimed to pharmacologically induce this protective PVD state in patients at high risk of progression.[10] This strategic focus on prevention in NPDR represented a significant departure from treatments targeting existing vitreomacular adhesion (VMA) or traction, such as the indication pursued for ocriplasmin.[3] While potentially addressing a larger patient population at risk, demonstrating long-term preventative efficacy posed a considerable clinical and regulatory challenge compared to treating an established condition.

Beyond the primary indication, Vitreosolve was also investigated or considered for its potential to liquefy the vitreous gel as an adjunct to pars plana vitrectomy surgery, potentially simplifying the surgical procedure.[12] Furthermore, an interesting secondary observation emerged from early clinical trials: patients treated with Vitreosolve reported a reduction or even complete elimination of symptomatic vitreous floaters.[10] While not the primary focus of development, this finding addressed a common patient complaint with few effective non-surgical treatments, hinting at a potential alternative therapeutic avenue that resonated with a significant unmet need.

D. Development Status

Despite progressing into late-stage clinical development, the program for Vitreosolve was ultimately discontinued during Phase 3 trials.[9] Correspondingly, the developer, Vitreoretinal Technologies, Inc., appears to be no longer operational, with database records indicating its status as "Out of Business".[17] The lack of recent company communications or website activity further supports this status.[18]

II. Mechanism of Action

A. Classification and Chemical Nature

Vitreosolve was classified as a non-enzymatic pharmacologic vitreolysis agent.[1] This distinguishes it from enzymatic agents that function by cleaving specific biomolecules within the vitreous or at the vitreoretinal interface (e.g., ocriplasmin targeting fibronectin and laminin, hyaluronidase targeting hyaluronan).[1] Vitreosolve was described as a proprietary formulation of a small molecule belonging to the carbomide family, specifically identified as being urea-based.[1] Due to its proprietary nature, the precise chemical structure was not disclosed in the available documentation.[1]

B. Action on Vitreous Structure

The vitreous humor derives its gel-like consistency and viscoelastic properties from a complex network primarily composed of water (98-99%), sparsely distributed collagen fibrils (types II, IX, V/XI), and space-filling glycosaminoglycans (GAGs), mainly hyaluronan (HA).[2] This network provides structural integrity but also mediates the pathological adhesions and tractions seen in various vitreoretinal diseases.[7]

Vitreosolve's mechanism was proposed to involve the disruption of this delicate collagen-HA structural network.[10] Unlike enzymes that break covalent bonds within specific substrates, Vitreosolve, being urea-based, likely functioned as a denaturant.[22] Urea is known to disrupt non-covalent interactions, particularly hydrogen bonds, which play a significant role in stabilizing the tertiary structure of proteins (like collagen) and the interactions between macromolecules (like collagen and HA) within the vitreous matrix and at the vitreoretinal interface.[22] This non-enzymatic, denaturation-based mechanism represents a fundamentally different approach to altering vitreous structure compared to enzymatic cleavage.[1] This distinction carries potential implications: a denaturant might act more broadly but perhaps less specifically than an enzyme, potentially affecting multiple interactions simultaneously but also raising concerns about off-target effects on retinal structures if specificity is lacking.

C. Induction of Liquefaction and PVD

The process of PVD naturally involves two concurrent events: the liquefaction (synchysis) of the vitreous gel and the weakening of adhesion (syneresis) between the posterior vitreous cortex and the retinal internal limiting membrane (ILM), allowing separation.[1] Effective pharmacologic vitreolysis ideally aims to induce both processes safely.[2]

Vitreosolve was classified as having both liquefactant (promoting gel liquefaction) and interfactant (promoting interface separation) properties.[3] By disrupting the collagen-HA network through interference with non-covalent bonds, Vitreosolve was expected to cause the release and diffusion of hyaluronan, leading to the collapse of the gel structure (liquefaction).[10] This breakdown would also eliminate the structural scaffold potentially required for pathological neovascularization in conditions like PDR.[10] Simultaneously, the disruption of adhesive forces at the vitreoretinal interface (interfactant activity), presumably also mediated by interference with non-covalent molecular interactions involving collagen and other ECM components, would facilitate the separation of the collapsing vitreous body from the retinal surface, thereby inducing PVD.[2] Theoretically, possessing both liquefactant and interfactant activities could make an agent more effective in achieving a complete and safe PVD compared to agents primarily targeting only liquefaction (like hyaluronidase) or only interface adhesion.[2] Failure to adequately weaken vitreoretinal adhesion while inducing liquefaction could potentially worsen existing traction.[3]

D. Pharmacokinetics

Limited pharmacokinetic information is available from the provided sources. One report indicated that following intravitreal injection, Vitreosolve was shown to concentrate in the vitreous for less than 72 hours.[10] This suggests a relatively short duration of action within the target compartment. The proprietary nature of the molecule limits a deeper understanding of its specific binding interactions, distribution, and clearance pathways.[1]

III. Clinical Development Program

A. Overview of Phases

Vitreosolve progressed through early-phase clinical testing into larger, late-stage trials. Documentation confirms the completion of Phase 1 and Phase 2 studies and the initiation of Phase 2/3 and Phase 3 trials designed to evaluate safety and efficacy for regulatory submission.[1] However, as previously noted, the late-stage program was ultimately terminated before completion.[9]

B. Key Clinical Trials

Several clinical trials involving Vitreosolve have been identified, primarily focusing on its efficacy in inducing PVD and its potential role in diabetic retinopathy:

• Early Unpublished Study: Preliminary results cited in reviews indicated PVD induction rates of 45% after one injection and 75% after two injections.[1]
• Phase 1/2 Studies: Provided initial safety data deemed "excellent" and reported an 83% total PVD induction rate.[10] Specific trial identifiers are not provided for these early studies.
• NCT00198549: A Phase 3 study evaluating safety and efficacy in retinopathy subjects. Status reported as Terminated.[26]
• NCT00664183 (PVD-301): A Phase 2/3 study titled "A Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects," specifically targeting NPDR. Status reported as Terminated.[1] This multinational trial included sites in the U.S. and India.[11]
• NCT00908778: A Phase 3 study titled "A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients." Status reported as Unknown.[9]
• PVD-302: Mentioned as a Phase II/III testing protocol alongside PVD-301, likely also terminated.[1]

The available information suggests inconsistencies in the reported status of these trials across different databases, though the overall program discontinuation is clear.[9] NCT00664183 and NCT00198549 are explicitly listed as terminated. The "Unknown" status for NCT00908778 might reflect incomplete database updates following program cessation.

Table 1: Summary of Key Vitreosolve Clinical Trials

ClinicalTrials.gov ID / Study Name	Phase	Status	Indication(s)	Key Design/Population Notes	Key Reported Outcomes/Endpoints (from snippets)	Source Snippets
Early Phase 1/2 Studies	1/2	Completed (Implied)	PVD Induction / NPDR / Floaters	Intravitreal injection	83% total PVD induction; Reduction/elimination of floaters; Excellent safety profile; No significant AEs	10
Early Unpublished Study	N/A	N/A	PVD Induction	Single 12 mg injection; Second injection at 30 days	45% PVD induction (1 inj); 75% PVD induction (2 inj)	1
NCT00198549	3	Terminated	Retinopathy	Safety and Efficacy Study	No results reported in snippets	26
NCT00664183 (PVD-301)	2/3	Terminated	NPDR without pre-existing PVD	Safety and Efficacy Study; Multinational (US, India)	No specific results reported in snippets; Trial terminated	1
PVD-302	2/3	Terminated (Implied)	NPDR without pre-existing PVD	Safety and Efficacy Study	No specific results reported in snippets; Trial terminated	1
NCT00908778	3	Unknown	PVD Induction in Retinopathy	Safety and Efficacy Study; Four intravitreal injections	No results reported in snippets	9

Note: Status and results are based solely on information within the provided snippets and may not reflect the final official trial records.

C. Target Populations and Design

The late-stage clinical trials (Phase 2/3 and Phase 3) primarily targeted adult patients with NPDR who did not have evidence of a pre-existing PVD.[1] This specific inclusion criterion underscores the program's focus on inducing PVD as a preventative measure against progression to PDR. The trials were conducted across multiple sites internationally, including locations in the United States and India.[11] The involvement of Indian sites like Aravind Eye Hospital, L V Prasad Eye Institute (LVPEI), and All India Institute of Medical Sciences (AIIMS) suggests a strategy to access a large diabetic patient pool, potentially facilitating faster enrollment and possibly reducing overall trial costs.[11] The typical dosing regimen involved one or two intravitreal injections administered over a one-month period, with a 12 mg dose being mentioned in relation to preliminary study results.[1] NCT00908778 specifically mentions evaluating four injections.[9]

IV. Efficacy Findings

A. PVD Induction

Data from early development stages suggested promising efficacy for Vitreosolve in inducing PVD. Preliminary, unpublished results indicated PVD induction in 45% of patients after a single 12 mg injection, rising to 75% following a second injection one month later.[1] Furthermore, pooled data from Phase 1/2 trials reported an 83% rate of total PVD induction.[10]

However, these encouraging early results must be contrasted with information emerging around the time of the Phase 3 program's termination. One source mentioned that the drug demonstrated efficacy in approximately 50% of patients, a figure cited in the context of the financial decision to halt development due to the cost of achieving statistical significance.[13] This discrepancy between the high rates reported earlier (75-83%) and the later ~50% figure is significant. It may suggest that the initial positive results were not fully replicated in the larger, more heterogeneous Phase 3 population, that the definition of successful PVD induction varied between studies, or that the threshold for demonstrating a statistically significant benefit over placebo in the pivotal trials proved difficult to meet, even with a noticeable biological effect. Direct comparison with other agents like ocriplasmin (which reported ~26.5% VMA resolution and ~13.4% total PVD induction at Day 28 in its pivotal trials for symptomatic VMA [13]) is challenging due to differences in patient populations, study endpoints, and mechanisms of action.

B. Prevention of PDR Progression

The intended primary benefit of Vitreosolve was the prevention of progression from NPDR to PDR. However, efficacy for this indication was largely inferred from the drug's ability to induce PVD, based on the well-established hypothesis that PVD is protective against diabetic retinal neovascularization.[4] The clinical trials were designed with the expectation that pharmacologically induced PVD would mimic the protective effect of spontaneous PVD.[10]

Crucially, due to the termination of the Phase 3 program before completion, long-term data directly demonstrating a statistically significant reduction in the rate of PDR progression in Vitreosolve-treated patients compared to a control group is not available from the provided documentation. Proving such a preventative endpoint typically requires large patient cohorts followed over extended periods (years), making these trials inherently complex, lengthy, and expensive.[10] The discontinuation linked to funding required for statistical significance underscores the challenges associated with validating preventative therapies in chronic, progressive diseases like diabetic retinopathy.[13]

C. Effect on Eye Floaters

A consistent secondary finding reported from early Vitreosolve clinical trials was a beneficial effect on vitreous floaters. Patients treated with the drug reported experiencing either a reduction in or complete elimination of their floaters.[10] Floaters, often caused by vitreous opacities or syneresis, are a common and bothersome symptom for many individuals, yet effective non-surgical treatments are limited. While presented somewhat anecdotally in the sources and not appearing to be a primary endpoint, this patient-reported outcome was highlighted as a potentially significant benefit.[21] This suggests a possible alternative indication or a valuable secondary benefit that might have enhanced the drug's profile had development continued, potentially offering a more readily demonstrable therapeutic effect compared to long-term PDR prevention.

V. Safety and Tolerability Profile

A. Early Clinical Data

Information regarding the safety of Vitreosolve primarily stems from its early clinical development phases. Reports based on Phase 1 and Phase 2 data described Vitreosolve as having an "excellent safety profile".[10] Furthermore, these sources stated that "no significant adverse events" had been reported during these initial stages of testing.[10]

B. Late-Stage Trial Data

Detailed safety and tolerability data from the larger Phase 3 patient population are absent in the provided documentation. This lack of information is a direct consequence of the trials (NCT00664183, NCT00198549) being terminated before completion and final reporting.[9] While early-phase safety results appeared favorable, it is important to recognize that larger trials with longer follow-up are necessary to fully characterize the safety profile of an investigational agent and detect less common or later-onset adverse events. The reason explicitly cited for the program's discontinuation relates to funding and statistical efficacy hurdles, not to emergent safety concerns identified during the Phase 3 studies.[13] However, without the complete Phase 3 safety dataset, a comprehensive assessment remains incomplete.

VI. Development Discontinuation

A. Trial Termination

The clinical development program for Vitreosolve was halted during its late stages. Specifically, Phase 3 trials NCT00664183 (PVD-301) and NCT00198549 were reported as terminated.[9] While the status of NCT00908778 was listed as unknown in some databases, the overall program did not proceed to regulatory submission or approval.[9]

B. Reasons for Discontinuation

The primary reason cited for the discontinuation of the Vitreosolve Phase 3 program was financial constraints related to achieving statistical significance. According to one report, investors declined to provide approximately $40 million in additional funding deemed necessary to demonstrate a statistically significant difference between Vitreosolve and placebo, even though the drug was reportedly inducing PVD in about 50% of patients.[13] This indicates that while a biological effect might have been present, the magnitude of the effect, variability in response, or the required sample size made achieving statistical proof challenging and costly within the available resources. The failure appears rooted in the difficulty of demonstrating robust efficacy in a large-scale trial setting and securing adequate funding, rather than being driven by safety issues identified in the late-stage trials.[13]

C. Developer Status

Following the discontinuation of the Vitreosolve program, the developing company, Vitreoretinal Technologies, Inc., appears to have ceased operations. Database records from March 2025 indicate the company's status as "Out of Business" or inactive, with Vitreosolve listed as "Discontinued" at Phase 3.[9] Searches for recent press releases or an active company website were unsuccessful, supporting the conclusion that the company is no longer active.[18] This outcome illustrates the vulnerability of clinical-stage biotechnology companies, particularly when facing setbacks with a lead asset in late-stage development.

VII. Conclusion and Perspectives

A. Summary of Vitreosolve

Vitreosolve was a non-enzymatic, urea-based small molecule developed by Vitreoretinal Technologies, Inc., for pharmacologic vitreolysis via intravitreal injection. Its proposed mechanism involved disrupting the vitreous collagen-hyaluronan network through non-covalent interactions, aiming to induce both liquefaction and vitreoretinal dehiscence. The primary development goal was the induction of PVD in patients with NPDR as a preventative measure against progression to PDR. Secondary potential applications included use as a surgical adjunct and, based on patient reports, the reduction of vitreous floaters. Early clinical trials showed promising PVD induction rates (up to 83%) and a favorable safety profile. However, the Phase 3 program was discontinued before completion, reportedly due to the substantial funding required to achieve statistical significance for the primary endpoint, despite evidence of biological activity in approximately half of the patients. The developing company subsequently ceased operations.

B. Broader Implications

The development and subsequent discontinuation of Vitreosolve offer several perspectives on the field of pharmacologic vitreolysis and drug development. It highlights the significant financial and scientific challenges inherent in bringing novel ophthalmic therapies to market, particularly those targeting preventative endpoints in chronic diseases like diabetic retinopathy. Achieving statistically significant efficacy in large Phase 3 trials requires substantial investment and robust clinical effects, and failure to meet these thresholds can halt development even if some biological activity is observed.[13]

Vitreosolve's journey also underscores the difficulties encountered in the broader field of pharmacologic vitreolysis. While the concept of non-surgical PVD induction holds great appeal for managing various vitreoretinal interface disorders [1], success has been limited. The failure of hyaluronidase for vitreous hemorrhage [1], the discontinuation of Vitreosolve [13], and the modest success rates and specific indications of the only approved agent, ocriplasmin [3], collectively point to the complexity of safely and effectively manipulating the vitreous and its interface with the retina using pharmacological means.

Furthermore, the consistent patient-reported improvement in floaters associated with Vitreosolve [10] serves as a reminder of the importance of patient-centric outcomes and the significant unmet need for non-invasive treatments for this common and often bothersome condition. While Vitreosolve did not reach the market, the challenges faced in its development provide valuable lessons regarding mechanism of action (non-enzymatic vs. enzymatic), the selection of appropriate clinical endpoints (treatment vs. prevention), the need for robust statistical power, and the economic realities of late-stage pharmaceutical R&D. Future efforts in pharmacologic vitreolysis may require more potent or targeted agents, improved patient selection strategies, or combination therapies to overcome the hurdles encountered by agents like Vitreosolve.

Works cited

1. Review and Perspectives on Pharmacological Vitreolysis, accessed April 30, 2025, https://karger.com/Article/PDF/354547
2. Pharmacologic Vitreolysis | VMR Institute, accessed April 30, 2025, https://www.vmrinstitute.com/wp-content/uploads/2013/08/Chapter-VI.A.Pharmacologic-Vitreolysis.pdf
3. Pharmacologic vitreolysis: New strategy for treatment of anomalous vitreo-macular adhesion - Baishideng Publishing Group, accessed April 30, 2025, https://www.wjgnet.com/2218-6239/full/v5/i3/99.htm
4. The Emerging Role of Pharmacologic Vitreolysis - Retinal Physician, accessed April 30, 2025, https://www.retinalphysician.com/issues/2010/march/the-emerging-role-of-pharmacologic-vitreolysis/
5. The Emerging Role of Pharmacologic Vitreolysis - VMR Institute, accessed April 30, 2025, https://www.vmrinstitute.com/wp-content/uploads/2013/08/Pharmacologic-Vitreolysis-Emerging.pdf
6. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: A review, accessed April 30, 2025, https://www.researchgate.net/publication/51614755_Emerging_nonsurgical_methods_for_the_treatment_of_vitreomacular_adhesion_A_review
7. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3162296/
8. Induction of posterior vitreous detachment (PVD) by non-enzymatic ..., accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7237681/
9. Vitreosolve - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/94277ae0b89c40b2b54420e7a6f96916
10. A New Drug to Combat PDR - Review of Optometry, accessed April 30, 2025, https://www.reviewofoptometry.com/article/a-new-drug-to-combat-pdr
11. AMRFReport_08_09.pdf - Aravind Eye Hospital, accessed April 30, 2025, https://aravind.org/wp-content/uploads/2019/04/AMRFReport_08_09.pdf
12. Patients enrolled into Phase III diabetic retinopathy drug trial - Ophthalmology Times Europe, accessed April 30, 2025, https://europe.ophthalmologytimes.com/view/patients-enrolled-phase-iii-diabetic-retinopathy-drug-trial
13. Ocriplasmin Update: Safety, Efficacy, and Usage - American ..., accessed April 30, 2025, https://www.aao.org/eyenet/article/ocriplasmin-update-safety-efficacy-usage
14. A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects | Clinical Research Trial Listing - CenterWatch, accessed April 30, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT00664183/a-safety-and-efficacy-study-of-vitreosolver-for-non-proliferative-diabetic-retinopathy-subjects
15. Vitreoretinal Technologies closes deal with De Novo Ventures - Ophthalmology Times, accessed April 30, 2025, https://www.ophthalmologytimes.com/view/vitreoretinal-technologies-closes-deal-de-novo-ventures
16. Vitreoretinal Technologies, Inc. Announces The Enrollment Of First, accessed April 30, 2025, https://www.ophthalmologyweb.com/1315-News/31556-Vitreoretinal-Technologies-Inc-Announces-The-Enrollment-Of-First-Patients-For-Its-Phase-III-Clinical-Trial-For-Vitreosolve-For-Diabetic-Retinopathy-Patients-In-The-U-S-And-India/
17. VitreoRetinal Technologies, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/organization/7a2cafc09c47eb13ef7c4ff0a60adc97
18. Vitreoretinal Technologies, Inc. - Press Release Distribution and Management, accessed April 30, 2025, https://www.globenewswire.com/search/organization/Vitreoretinal%2520Technologies%CE%B4%2520Inc%C2%A7
19. (PDF) Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/263928302_Molecular_Mechanisms_of_Diabetic_Retinopathy_General_Preventive_Strategies_and_Novel_Therapeutic_Targets
20. Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4106080/
21. Injections have an important role in optometry, speaker says - Healio, accessed April 30, 2025, https://www.healio.com/news/optometry/20130305/talleyseco_10_3928_1081_597x_20130301_01_1058469
22. engineering the vitreous humor, accessed April 30, 2025, https://thesis.library.caltech.edu/974/4/CSN_CH4.pdf
23. Vitreoretinal Technologies Inc. - BioCentury Company Profiles - BCIQ, accessed April 30, 2025, https://profiles.biocentury.com/companies/vitreoretinal_technologies_inc
24. VitreoRetinal Technologies Inc. | Insights, accessed April 30, 2025, https://insights.citeline.com/companies/vitreoretinal-technologies-inc/
25. Pharmacologic Vitreolysis—Premise and Promise of the First Decade - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/26654123_Pharmacologic_Vitreolysis-Premise_and_Promise_of_the_First_Decade
26. Evaluation of Vitrase as an Adjuvant to Increase - ClinConnect, accessed April 30, 2025, https://clinconnect.io/trials/NCT00198549